End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
52.62 CNY | -0.44% | -5.22% | -38.83% |
Apr. 29 | MGI Tech Showcases Life Science Excellence At ESCMID Global 2024 with Latest DNBSEQ-E25 Sequencer | CI |
Apr. 28 | MGI Tech Co. Ltd. Opens Customer Experience Center in Brazil | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 63% by 2026.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-38.83% | 2.99B | - | ||
+7.87% | 219B | B | ||
+11.83% | 192B | B- | ||
+18.87% | 142B | B- | ||
+30.03% | 111B | A- | ||
+2.36% | 65.32B | A- | ||
+14.15% | 52.45B | B+ | ||
+2.68% | 49.8B | B+ | ||
+6.60% | 43.43B | A | ||
+1.85% | 35.95B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 688114 Stock
- Ratings MGI Tech Co., Ltd.